HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DCM-Dex-CDDP

structure in first source

Also Known As:

dicarboxymethyl-dextran-cisplatin

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ohya, Y: 2 articles (01/2001 - 01/2000)
2.	Ouchi, T: 2 articles (01/2001 - 01/2000)
3.	Nagatomi, K: 1 article (01/2001)
4.	Oue, H: 1 article (01/2001)
5.	Ichikawa, M: 1 article (01/2000)
6.	Ichinose, K: 1 article (01/2000)
7.	Kanematsu, T: 1 article (01/2000)
8.	Nakashima, M: 1 article (01/2000)
9.	Tomiyama, N: 1 article (01/2000)

Related Diseases

1.	Neoplasms (Cancer) 07/01/1999 - "DCM-Dex/CDDP thus has potential as a macromolecular derivative of CDDP for passive tumor targeting." 01/01/2000 - "These results indicate that DCM-Dex/CDDP may therefore be a potentially effective cancer chemotherapy." 01/01/2001 - "We previously reported that a macromolecular prodrug synthesized by immobilizing cisplatin (CDDP) to dextran (Dex) through six-membered chelate-type coordination bond (DCM-Dex/CDDP conjugate) showed a significantly longer half-life in bloodstream and excellent in vivo tumor growth inhibitory effect against mice bearing Colon 26 cancer cells. "
2.	Hepatocellular Carcinoma (Hepatoma) 01/01/2001 - "In this report, to provide DCM-Dex/CDDP conjugate having targetability to hepatoma cells, we designed a new macromolecular prodrug of CDDP using dextran having branched galactose units (Gal4As, four branched galactose residues), DCM-Dex/Gal4A/CDDP conjugate. "

Related Drugs and Biologics

1.	Prodrugs
2.	Galactose (Galactopyranose)
3.	Dextrans (Dextran)
4.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)